Strategic Wealth Partners Ltd. Decreases Stake in Hims & Hers Health, Inc. (NYSE:HIMS)

Strategic Wealth Partners Ltd. trimmed its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 75.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 27,042 shares of the company's stock after selling 82,157 shares during the quarter. Strategic Wealth Partners Ltd.'s holdings in Hims & Hers Health were worth $654,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the business. Means Investment CO. Inc. grew its stake in shares of Hims & Hers Health by 23.5% during the 4th quarter. Means Investment CO. Inc. now owns 50,040 shares of the company's stock valued at $1,210,000 after acquiring an additional 9,508 shares during the period. Raymond James Financial Inc. bought a new position in shares of Hims & Hers Health during the 4th quarter valued at approximately $18,048,000. State of Alaska Department of Revenue bought a new position in shares of Hims & Hers Health during the 4th quarter valued at approximately $2,628,000. Pacer Advisors Inc. purchased a new position in Hims & Hers Health in the 4th quarter worth approximately $374,000. Finally, Louisiana State Employees Retirement System purchased a new position in Hims & Hers Health in the 4th quarter worth approximately $2,234,000. 63.52% of the stock is currently owned by institutional investors.

Hims & Hers Health Price Performance

Shares of HIMS traded down $1.13 during midday trading on Tuesday, hitting $61.21. The stock had a trading volume of 35,648,545 shares, compared to its average volume of 19,324,176. Hims & Hers Health, Inc. has a 1 year low of $13.47 and a 1 year high of $72.98. The firm has a market cap of $13.70 billion, a PE ratio of 139.12 and a beta of 1.84. The stock's 50 day moving average is $36.60 and its 200 day moving average is $34.38.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its earnings results on Monday, May 5th. The company reported $0.20 earnings per share for the quarter, topping analysts' consensus estimates of $0.12 by $0.08. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The business had revenue of $586.01 million for the quarter, compared to analyst estimates of $535.21 million. During the same quarter last year, the firm posted $0.05 earnings per share. The business's revenue was up 110.7% compared to the same quarter last year. As a group, equities research analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently commented on HIMS shares. Truist Financial lowered their price target on Hims & Hers Health from $39.00 to $33.00 and set a "hold" rating on the stock in a report on Thursday, April 10th. Piper Sandler reissued a "neutral" rating and issued a $39.00 target price (up previously from $35.00) on shares of Hims & Hers Health in a report on Tuesday, May 6th. Leerink Partners boosted their target price on shares of Hims & Hers Health from $24.00 to $40.00 and gave the stock a "market perform" rating in a report on Tuesday, February 25th. Canaccord Genuity Group boosted their target price on shares of Hims & Hers Health from $38.00 to $68.00 and gave the stock a "buy" rating in a report on Wednesday, February 19th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $61.00 target price on shares of Hims & Hers Health in a report on Tuesday, May 6th. Two analysts have rated the stock with a sell rating, eight have given a hold rating and three have assigned a buy rating to the company's stock. According to data from MarketBeat, Hims & Hers Health has a consensus rating of "Hold" and an average target price of $37.67.

Insiders Place Their Bets

In other Hims & Hers Health news, insider Patrick Harrison Carroll sold 23,287 shares of Hims & Hers Health stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $34.31, for a total value of $798,976.97. Following the transaction, the insider now owns 209,661 shares in the company, valued at $7,193,468.91. The trade was a 10.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Andrew Dudum sold 47,534 shares of Hims & Hers Health stock in a transaction dated Friday, May 16th. The shares were sold at an average price of $58.25, for a total value of $2,768,855.50. Following the completion of the transaction, the chief executive officer now owns 285,194 shares in the company, valued at $16,612,550.50. This trade represents a 14.29% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 618,936 shares of company stock worth $25,182,692 over the last 90 days. Company insiders own 13.71% of the company's stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.